Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI® IV in China and a Co-Detailing collaboration in Shanghai

Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI IV in China and a Co–Detailing collaboration in Shanghai

Lugano, Switzerland, and Beijing, China, May 9, 2019: Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products, and Mundipharma China Pharmaceutical, the Chinese market leader of pain management, today announce the availability of ALOXI IV in China.

This is Helsinn's first cancer supportive care product to be launched in the Chinese market, and for which Mundipharma China Pharmaceutical has exclusive marketing, promotion and sales rights. This product was approved by the National Medical Products Administration (NMPA) in November 2018.

The launch of ALOXI IV in China, has also seen the initiation of a long co–detailing collaboration with Helsinn Pharmaceuticals (Beijing) Co., Ltd. in the municipality of Shanghai for ALOXI IV and other future cancer care products in the Chinese market.
Andrea Meoli, Helsinn Group Chief Commercial Officer, commented: "ALOXI IV is the first cancer supportive care product that we make available to Chinese patients. Since its launch in the other countries, ALOXI has been effectively used for the prevention of CINV, helping to define the standard of care for the condition, and we are delighted that it is now becoming available to patients in China. We are pleased to be collaborating with Mundipharma China Pharmaceutical, a strategic partner, in introducing this product in China and co–detailing it in Shanghai and thereby helping patients in China to benefit from this treatment option."

"The Launch of ALOXI IV identifies expansion of strategic cooperation between Helsinn and Mundipharma China Pharmaceutical." Said Peter Wang, General Manager, Mundipharma Pharmaceutical Greater China, "I believe there will be more CINV products with cutting–edge technologies to be brought into China market through the joint efforts of both sides, which will benefit more Chinese cancer patients."

END

About ALOXI (palonosetron HCI)

For China:

ALOXI injection 0.25 mg/5 ml was approved on November 8th, 2018 in China and is indicated in adults for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy. It is also indicated in pediatric patients aged 1 month to less than 17 years for the prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy.

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early–stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco, and China, as well as a product presence in approximately 190 countries globally.

To learn more about Helsinn Group please visit www.helsinn.com

About Mundipharma China Pharmaceutical

Mundipharma China Pharmaceutical was established in the year of 1993 and has been dedicated to the organic growth of the pain segment in China for decades. "Bring More to Life" is our aspiration; caring for lives and serving the society is our social responsibilities. Innovation, patient–centric, and entrepreneurship are in our DNAs.

In the future, Mundipharma China will continue to explore in pain management field and expand its business into new fields, including CINV, transplantation immunology, oncology, respiratory, consumer health and etc. We'll make unremitting efforts to providing innovative products and fulfilling our social responsibilities, ultimately to realize our vision of "Bring More to Life".

For more information, please refer to: http://www.mundipharma.com.cn

For more information:

Helsinn Group Media Contact:

Paola Bonvicini

Group Head of Communication

Lugano, Switzerland

Tel: +41 (0) 91 985 21 21

Email: Info–hhc@helsinn.com

For more information, please visit www.helsinn.com and follow us on Twitter, LinkedIn and Vimeo.

Mundipharma China Pharmaceutical Contact:

Kylie Gao,

PR Director

Beijing, China

Tel: +86(10) 6563 6785

Email: kylie.gao@mundipharma.com.cn

Comments are closed

RSS Daily Times Nigeria

  • Residents in Syria’s embattled Idlib hold anti-UN protest
    Hundreds of people in Syria’s embattled North-East province of Idlib on Friday took to the streets to protest against the UN Security Council’s failure to adopt a ceasefire resolution. Idlib, Syria’s last key rebel stronghold, had since in April, been the target of a military government campaign supported by allied Russia. The 15-member Security Council […]
  • Applicant docked for stealing phone
    A 22-year-old applicant, Danlami Ibrahim, was on Friday arraigned before a Magistrates’ Court in Minna for allegedly stealing a phone. Ibrahim is standing trial on two-count charge of criminal conspiracy and theft, contrary to sections 97 and 288 of the penal code law Police Prosecutor, Insp. Thomas Peter, told the court that the accused conspired […]
  • Maternal mortality: Rotary donates medical items to FCT
    Rotary International Club, District 9125, on Friday donated medical items to the FCT Administration to reduce maternal and child death in the territory. Dr Kolawole Owoka, who led other members of the club on a courtesy visit to the acting Executive Secretary, FCT Health and Human Services Secretariat (HHSS), Mr Musa Abdulrahim, said that the […]
  • Group to sensitise Ikorodu youths on dangers of engaging in crimes
    Dr Fatai Abatan, President, Ikorodu Division Youths Initiative Movement (IDYIM), said the group would soon organise series of orientation programmes to intimate youths on the consequences of engaging in crimes. Speaking during the inauguration of IDYIM Board of Trustees in Ikorodu on Friday, Abatan said that the group planned to establish a vocational centre where […]

Weather for Abuja

The location could not be found.

RSS Vanguard News

  • United States to send troops to bolster Saudi defences
    United States President Donald Trump on Friday approved sending American troops to bolster Saudi Arabia’s air defences after the largest-ever attack on the kingdom’s oil facilities, which Washington has squarely blamed on Iran. The Pentagon said the deployment would involve a moderate number of troops – not numbering thousands – and would be primarily defensive […]
  • Why the nation slept through the ‘Landmark judgement’
    Several years ago, I was in a plane with two veteran journalists, Chief Eddy Aderinokun and Mr Olu Akaraogun. We were on our way to Yola to see Alhaji BamangaTukur. The late Akaraogun, one of the most versatile journalists of his generation, sat next to me. As usual, we were discussing politics and the state […]
  • Toni Conceicao: Former Portugal international named Cameroon coach
    Former Portugal international Toni Conceicao has been named as the new coach of the Cameroon national team, sports minister Narcisse Mouelle Kombi announced on Friday. Continue reading Toni Conceicao: Former Portugal international named Cameroon coach at Vanguard News.

© 2019 Nigeria Newsline. All Rights Reserved. Log in -